Morphic Therapeutic announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.
Jefferies London Healthcare Conference Fireside Chat
Date: Tuesday, November 14, 2023
Time: 5:00 PM GMT/12:00 PM ET
A live webcast of the presentation will be available on the Investor section of the Morphic website. An archived replay will be available on the company’s website following the conference.
Evercore ISI HealthCONx Conference Presentation
Date: Thursday, November 30, 2023
Time: 9:10 AM ET
A live webcast of the presentation will be available on the Investor section of the Morphic website. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
